The FDA has accepted the NDA for ulixacaltamide HCl, a selective T-type calcium channel inhibitor for essential tremor, following positive phase 3 Essential3 trial results.
ULIXACALTAMIDE maintained response in essential tremor in a Phase III randomized withdrawal study at AAN 2026. The topline ...
Frequent hand tremors are often overlooked, with many attributing them to fatigue or the aging process. However, persistent tremors can indicate significant deficiencies in essential vitamins and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results